Status:
COMPLETED
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
20-80 years
Phase:
PHASE3
Brief Summary
This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350 patients (approxim...
Eligibility Criteria
Inclusion
- Patients who successfully complete the core study (Protocol 1303)
- Outpatients
Exclusion
- Presence of crucial protocol violation in Protocol 1303
- Patients who experienced any adverse events considered serious and drug related in Protocol 1303.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
362 Patients enrolled
Trial Details
Trial ID
NCT00338936
Start Date
May 1 2006
End Date
September 1 2007
Last Update
November 8 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.